Energy
TMK Energy raises July gas output to 778 cubic metres
TMK Energy (ASX:TMK) reported that average gas production at its Gurvantes XXXV Pilot Well Project in Mongolia reached 778 cubic metres per day in July.
Brie Carter
TV Presenter & Finance EditorTV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Contact
Contact editorial teamArticles by Brie Carter
Law and legal
BitMart faces insolvency claim over frozen withdrawals
BitMart is facing an insolvency claim after reports that customer withdrawals were frozen on the crypto exchange.
Mining
Kuniko secures 51% interest in Commonwealth Project
Kuniko (ASX:KNI) secured a 51% ownership and control stake in the Commonwealth-Silica Hill Gold-Silver-Copper Project.
Cryptocurrency
Coinsbuy confirms breach after US$79M loss
Coinsbuy confirmed a security breach after wallets were reportedly drained of about US$79 million in digital assets.
Financial
National Australia Bank announces double executive leadership exit
National Australia Bank (ASX:NAB) announced two executive departures, reducing its leadership team by one.
Cryptocurrency
Trump Media Bitcoin losses reach US$361M
Trump Media & Technology Group reported a US$361 million unrealised loss on its Bitcoin (CRYPTO:BTC) holdings as the value of its crypto treasury declined.
Cryptocurrency
Polymarket faces probe over US$5M trade
US regulators are investigating a US$5 million Polymarket trade linked to Venezuelan President Nicolás Maduro’s political future.
Technology
South Australia launches $3M AI commission
The South Australian government has announced an $3 million royal commission into artificial intelligence starting on Oct. 1.
Health
Jazz to acquire Actio for $820M, expanding epilepsy drug portfolio
Jazz Pharmaceuticals (NASDAQ:JAZZ) agreed to acquire privately held Actio Biosciences for $820 million upfront, adding the clinical-stage epilepsy candidate ABS-1230 to its rare neurological disease portfolio.
Health
Axsome revenue grows 46% to $218.4 million
Axsome Therapeutics (NASDAQ:AXSM) reported Q2 2026 total net product revenue of $218.4 million, up 46% year over year, led by continued growth from AUVELITY.